← Back to Search

Taxane Chemotherapy

1 for Prostate Cancer

Phase 1 & 2
Waitlist Available
Led By Michael J Morris, M.D.
Research Sponsored by Cytogen Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
is safety and tolerability of the combination treatment
Secondary outcome measures
Tumor response will be assessed when possible using RECIST criteria.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Cytogen CorporationLead Sponsor
5 Previous Clinical Trials
115 Total Patients Enrolled
2 Trials studying Prostate Cancer
45 Patients Enrolled for Prostate Cancer
Michael J Morris, M.D.Principal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025